Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... (PRWEB) April 28, 2015 The ... a Massachusetts-based multi-stakeholder, non-profit organization dedicated to transforming ... a shared global system for clinical research, announced ... an innovative new type of clinical research event ... of clinical research is changing,” said Greg Koski, ...
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... Deadly viruses such as Ebola are ... the University City Science Center's Port business ... With a $4.5 million Phase 2 SBIR grant from ... Therapeutics is focused on therapies for unmet medical ... is developing first-in-class protease inhibitors based on a technology ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
Breaking Biology Technology:ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2
... COLUMBIA, Md., Sept. 2 ACell, Inc. is announcing ... , , The conference will be held ... Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer ... 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The ...
... HAYWARD, Calif., Sept. 2 Advanced Cell Diagnostics, Inc. ... of its Series A equity financing from Morningside Ventures, bringing ... , , ACD will use the funds ... on the company,s patent pending RNAscope(TM) technology. "This second closing ...
... , , INDIANAPOLIS, Sept. 2 ... announced that, effective October 1, 2009, it would increase the ... kg for all non-contract customers or as existing contracts permit. ... invest in expanding global supply for the high performance, reducing ...
Cached Biology Technology:ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference 2ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development 2
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 6, 2013) -- Researchers at Weill Cornell Medical College have ... circuits in a developing brain -- gaining unprecedented insight into ... from autism to mental retardation. In the journal ... faulty wiring occurs when RNA molecules embedded in a growing ...
... of treatment for patients with end-stage liver disease, the 12th ... research from the Icahn School of Medicine at Mount Sinai, ... today, suggests that it may one day become possible to ... disease. Investigators discovered that a human embryonic stem cell can ...
... of vitamin D are associated with high levels of hepatitis ... , a journal of the American Association for the Study ... HBV levels point to a link in these variables among ... are available, HBV still remains one of the most significant ...
Cached Biology News:Researchers discover how brain circuits can become miswired during development 2Researchers discover how brain circuits can become miswired during development 3Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration 2Vitamin D deficiency may help spread of hepatitis B throughout liver 2
... mir Vana miRNA Bioarray Essentials Kit provides ... and post-hybridization washing of the mir Vana ... has been labeled using Ambions mir Vana ... positive control miRNA (Bioarray ID BA10001) that should ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: box ...
... The InnoCyte Laminin-Based 96-well Cell Invasion Assay ... of cells using laminin as a significant ... anti-metastatic agents in vitro in a convenient, ... size is appropriate for all types of ...
Biology Products: